San Ramon, Calif. – The Cooper Companies (NASDAQ: COO) announced its fiscal third‑quarter results on Wednesday, delivering a profit of $432.8 million, or $2.24 per share. Adjusted earnings, which strip out one‑time gains and costs, came in at $1.15 per share, comfortably beating the consensus estimate of $1.11 per share from seven analysts surveyed by Zacks Investment Research.
Revenue falls short of expectations
Despite the earnings beat, the company’s revenue for the quarter registered $1.07 billion, missing the $1.10 billion average forecast from six Zacks analysts. The shortfall reflects a modest slowdown in sales of the firm’s surgical and contact‑lens products.
Guidance for the next quarter and full year
Looking ahead, Cooper Companies expects earnings per share for the quarter ending in October to range between $1.05 and $1.09. Revenue for that period is projected to fall between $1.06 billion and $1.08 billion.
For the full fiscal year, the company anticipates earnings per share of $4.51 to $4.55 and total revenue of $4.23 billion to $4.25 billion. Those ranges suggest a steady, if modest, growth trajectory despite the recent revenue miss.
Analyst perspective
Analysts noted that the earnings beat underscores the resilience of Cooper’s core product lines, even as the company works to close the gap between revenue expectations and actual sales. The firm’s ability to generate profit above consensus while navigating a tighter revenue environment was highlighted as a positive sign for shareholders.
Investors will be watching the upcoming quarter closely to see whether the company can translate its earnings strength into stronger top‑line performance. The guidance provided suggests management is confident in its ability to deliver consistent results while managing costs.
Company background
Founded in 1958, The Cooper Companies is a global medical device firm that designs, manufactures, and markets surgical and vision‑care products. Its portfolio includes contact lenses, intra‑ocular lenses, and a range of surgical devices used in ophthalmology and other specialties.
The company’s headquarters remain in San Ramon, California, where it continues to employ a sizable workforce focused on research, development, and manufacturing.
What this means for the market
While the revenue miss may raise questions about short‑term sales momentum, the earnings beat and forward guidance suggest the firm is maintaining profitability and positioning itself for steady growth. Market participants will likely weigh the guidance against broader industry trends in medical devices and vision care.
Overall, Cooper Companies’ third‑quarter performance reflects a balance of solid earnings and a need to address revenue challenges, a dynamic that many mid‑size health‑care firms are navigating in today’s market environment.
Original reporting: Alexandria, VA News – WTOP News — read the source article.
